Atrium Therapeutics (RNA) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T22:52:35.176Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:52:35.176Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -95,711,000
Quote market capitalization: 136,674,088
Total debt · period ending 2026-06-30: 1,683,000
Cash · period ending 2026-06-30: 72,645,000

FMP input reference: 87d00981f6afc2d6fb42b8babadf75d30967326f42a5e12d4c63051d6ceded83

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

RNA EBITDA Yield Metrics

EBITDA YIELD

N/A

RNA Competitors' EBITDA Yield

RNA

Atrium Therapeutics, Inc.

Current

Market Cap

$136.67M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OGI

Organigram Global Inc.

vs RNA

Market Cap

$136.57M

EBITDA Yield

9.38%

TTM Avg

3.05%

3Y Avg

2.67%

5Y Avg

2.31%

KRMD

KORU Medical Systems, Inc.

vs RNA

Market Cap

$137.80M

EBITDA Yield

N/A

TTM Avg

0.23%

3Y Avg

1.76%

5Y Avg

3.40%

IMRX

Immuneering Corporation

vs RNA

Market Cap

$139.04M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACOG

Alpha Cognition Inc

vs RNA

Market Cap

$139.47M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STRO

Sutro Biopharma, Inc.

vs RNA

Market Cap

$139.84M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FRNM

Freenome, Inc.

vs RNA

Market Cap

$133.45M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFMD

LifeMD, Inc.

vs RNA

Market Cap

$132.03M

EBITDA Yield

N/A

TTM Avg

4.68%

3Y Avg

4.68%

5Y Avg

4.68%

AIRS

AirSculpt Technologies, Inc.

vs RNA

Market Cap

$131.21M

EBITDA Yield

0.23%

TTM Avg

0.33%

3Y Avg

3.24%

5Y Avg

2.95%

HCAT

Health Catalyst, Inc.

vs RNA

Market Cap

$130.79M

EBITDA Yield

1.34%

TTM Avg

1.37%

3Y Avg

1.37%

5Y Avg

1.37%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Atrium Therapeutics, Inc. (RNA)	$136.67M	N/A	N/A	N/A	N/A
Organigram Global Inc. (OGI)vs ›	$136.57M	9.38%	3.05%	2.67%	2.31%
KORU Medical Systems, Inc. (KRMD)vs ›	$137.80M	N/A	0.23%	1.76%	3.40%
Immuneering Corporation (IMRX)vs ›	$139.04M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.47M	N/A	N/A	N/A	N/A
Sutro Biopharma, Inc. (STRO)vs ›	$139.84M	N/A	N/A	N/A	N/A
Freenome, Inc. (FRNM)vs ›	$133.45M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMD)vs ›	$132.03M	N/A	4.68%	4.68%	4.68%
AirSculpt Technologies, Inc. (AIRS)vs ›	$131.21M	0.23%	0.33%	3.24%	2.95%
Health Catalyst, Inc. (HCAT)vs ›	$130.79M	1.34%	1.37%	1.37%	1.37%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

RNA EBITDA Yield Metrics

RNA Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics